Citation Impact
Citing Papers
Preferential Generation of Follicular B Helper T Cells from Foxp3 + T Cells in Gut Peyer's Patches
2009 StandoutScienceNobel
Taking Cell-Matrix Adhesions to the Third Dimension
2001 StandoutScience
Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program
2007 StandoutNobel
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Tumour-cell invasion and migration: diversity and escape mechanisms
2003 Standout
MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers
2019
Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines
2000
AML1, the Target of Multiple Chromosomal Translocations in Human Leukemia, Is Essential for Normal Fetal Liver Hematopoiesis
1996 Standout
Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality
2009 StandoutNobel
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
2013 Standout
Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells
2001
Function of PU.1 (Spi-1), C/EBP, and AML1 in Early Myelopoiesis: Regulation of Multiple Myeloid CSF Receptor Promoters
1996
Siglecs and their roles in the immune system
2007 Standout
The evolving role of natural products in drug discovery
2005 Standout
Improving the efficacy of antibody-based cancer therapies
2001
A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia
2003
The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and/or ZAP-70 expression
2003
Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups
2005
High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)
2001
Current management and challenges of malignant disease in the CNS in paediatric leukaemia
2008
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Prodrug Strategies in Anticancer Chemotherapy
2007
The past and future of CD33 as therapeutic target in acute myeloid leukemia
2014
New approaches to antibody therapy
2000
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
2021 Standout
Cancer Statistics, 2006
2006 Standout
CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
2019 StandoutNobel
Early Phase I/II Trials with Gemtuzumab Ozogamicin (Mylotarg®) in Acute Myeloid Leukemia
2002
Monoclonal antibodies: versatile platforms for cancer immunotherapy
2010
Cancer stem cells revisited
2017 Standout
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Survivors of childhood and adolescent cancer: life-long risks and responsibilities
2013 Standout
Antibody targeted drugs as cancer therapeutics
2006
Human acute myeloid leukemia stem cells
2003
Follicular B helper T cells in antibody responses and autoimmunity
2005
Immune attack: the role of inflammation in Alzheimer disease
2015 Standout
Cancer genes and the pathways they control
2004 Standout
Antibody therapy of cancer
2012 Standout
Cell-matrix contact structures
2001
Polymer conjugates as anticancer nanomedicines
2006 Standout
Targeting multidrug resistance in cancer
2006 Standout
Cancer nanomedicines: So many papers and so few drugs!
2012
Transient expression of the NG2 proteoglycan by a subpopulation of activated macrophages in an excitotoxic hippocampal lesion
2001
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Salvage Therapy for Refractory or Relapsed Acute Lymphocytic Leukemia
2001
Antibody-targeted chemotherapy with immunoconjugates of calicheamicin
2003
Revised guideline on immunophenotyping in acute leukaemias and chronic lymphoproliferative disorders
2002
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
2016
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Molecular mechanisms of T cell co-stimulation and co-inhibition
2013 Standout
c-Kit Point mutation in patients with myeloproliferative disorders
1997
Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia
2001
Photodynamic therapy of cancer: An update
2011 Standout
Childhood Leukemias
1995
The Management of Neoplastic Disorders of Haematopoeisis in Children with Down's Syndrome
2000
IgG4-related disease
2014 Standout
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Down's syndrome
2003 Standout
Multi-Modality Therapeutics with Potent Anti-Tumor Effects: Photochemical Internalization Enhances Delivery of the Fusion Toxin scFvMEL/rGel
2009
Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3‐kinase‐mediated intracellular signaling
2004
Notch1 Expression in Early Lymphopoiesis Influences B versus T Lineage Determination
1999 Standout
Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 μl) blood samples
2007
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
2014 Standout
New developments for antibody-drug conjugate-based therapeutic approaches
2016
FcRn: the neonatal Fc receptor comes of age
2007 Standout
Gold nanoparticles in biomedical applications: recent advances and perspectives
2011 Standout
Mylotarg: antibody-targeted chemotherapy comes of age
2001
Monoclonal antibodies for cancer immunotherapy
2009
Arming antibodies: prospects and challenges for immunoconjugates
2005
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence
2005
The Biosynthetic Logic of Polyketide Diversity
2009 Standout
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
2003 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
The CC Chemokine Receptor 4 as a Novel Specific Molecular Target for Immunotherapy in Adult T-Cell Leukemia/Lymphoma
2004
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
2013
Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update
2011
Acute Myeloid Leukemia
2015 Standout
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse
2001
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma
2012 StandoutNobel
New Strategies for Fluorescent Probe Design in Medical Diagnostic Imaging
2009 Standout
Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2
2000
Biology of Gastrointestinal Stromal Tumors
2004 Standout
IL-17 and Th17 Cells
2009 Standout
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
2001
VENO-OCCLUSIVE DISEASE OF THE LIVER
1955
Inflammatory Blockade Restores Adult Hippocampal Neurogenesis
2003 StandoutScience
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Overview of monoclonal antibodies in cancer therapy: present and promise
2005
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
A human homologue of the Drosophila developmental gene, Notch, is expressed in CD34+ hematopoietic precursors
1994
Granules of the Human Neutrophilic Polymorphonuclear Leukocyte
1997 Standout
Gemtuzumab ozogamicin for acute myeloid leukemia
2017
Biosynthesis of the Enediyne Antitumor Antibiotic C-1027
2002 Science
Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2
2000
Metal–Organic Frameworks in Biomedicine
2011 Standout
pH-Operated Nanopistons on the Surfaces of Mesoporous Silica Nanoparticles
2010 StandoutNobel
Regulatory roles of IL-10–producing human follicular T cells
2019 StandoutNobel
PU.1 (Spi-1) and C/EBPα Regulate Expression of the Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Gene
1995
The World Health Organization (WHO) classification of the myeloid neoplasms
2002 Standout
Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16)(p13q22) exhibits a specific immunophenotype with CD2 expression
1993
Works of FO Smith being referenced
Transjugular intrahepatic portosystemic shunting (TIPS) for treatment of severe hepatic veno-occlusive disease.
1996
Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891
2005
The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23
1996
Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate
1999
Expression of lymphoid-associated cell surface antigens by childhood acute myeloid leukemia cells lacks prognostic significance
1992
Cell surface expression of c-kit receptors by childhood acute myeloid leukemia blasts is not of prognostic value: a report from the Childrens Cancer Group
1994
Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate
1999
Ontogeny of hematopoietic stem cell development: reciprocal expression of CD33 and a novel molecule by maturing myeloid and erythroid progenitors
1993
Differences in the frequency of normal and clonal precursors of colony- forming cells in chronic myelogenous leukemia and acute myelogenous leukemia
1992